Business Update Positive

2026-11-07 19:19

Financial Performance - Q2 FY27 Revenue from operations reached ₹271 Cr, growing 32% YoY; H1 FY27 revenue crossed ₹507 Cr, up 27% YoY. - Q2 EBITDA stood at ₹71 Cr (margin at ~26% vs 29% in Q2 FY26) impacted by upfront operational costs of new rollouts; PAT stood at ₹25 Cr. Receivables & Working Capital - Receivables increased to ~₹470 Cr as of September 30, with visibility on ~₹200 Cr collections expected during Q3 FY27. - Target to bring working capital cycle back to historical levels of 90–100 days driven by cash-based revenue expansion. Management Guidance & Outlook - Targeting cash-based revenues to contribute 40%–45% of overall mix (~₹400 Cr) by end of FY27, aspiring towards 50%–60% over 3 years. - Retail diagnostic segment expected to reach double-digit revenue share by FY27-end and move towards ~20% over 2–3 years, achieving EBITDA breakeven/profitability upon FY27 exit. - Rajasthan project annualized potential estimated at ~₹250 Cr, with 75%–80% implementation completed. Growth Drivers - Pipeline addition of cash-based PPP tenders including Punjab PET-CT and 34 CT scans in Himachal Pradesh. - Strategic tie-up with Apulki Healthcare across a ~2,000-bed hospital network. - Promoter commitment reinforced via ₹92 Cr convertible warrants allotment (₹23 Cr paid up).

Business Update Positive

2026-11-07 19:18

Financial & Operational Highlights - H1 FY27 revenue crossed ₹507 Cr (up 27% YoY), while Q2 FY27 revenue reached ₹271 Cr (up 32% YoY). - Q2 FY27 EBITDA stood at ₹72 Cr with a 27% margin; PAT reached ₹25 Cr (9% margin). - Retail business delivered 35% YoY revenue growth to ₹23.5 Cr in Q2 FY27, contributing ~9% of group revenues. Working Capital & Receivables - Trade receivables stood at ~₹470 Cr as of September 30, 2026, primarily due to project expansion and state disbursement delays. - Management highlighted visibility of collecting ~₹200 Cr in dues during Q3 FY27. - Target is to bring working capital days back down to historical levels of 90–100 days. Growth Drivers & Strategic Initiatives - Rajasthan project execution reached 75–80% completion, with an annualized revenue potential of ~₹250 Cr. - Shifting focus toward cash-based PPP projects and retail, targeting 40–45% (~₹400 Cr) cash revenue mix by end of FY27. - Secured cash-based tenders including 34 CT scanners in Himachal Pradesh and a PET-CT diagnostic project in Punjab. - Promoters demonstrated commitment via ₹92 Cr convertible warrant allotment (₹23 Cr already invested). Management Guidance & Outlook - Margin expansion expected in upcoming quarters as new projects mature and operating leverage kicks in. - Retail division is projected to achieve full EBITDA break-even and profitability by Q3/Q4 FY27, targeting higher-teens revenue contribution in 2–3 years. - Management targets higher-teens ROCE backed by cost rationalization and asset-light models.

Routine Neutral

2026-11-03 19:12

- Krsnaa Diagnostics Limited has informed about the shifting of the corporate office of its Registrar and Share Transfer Agent (RTA), KFin Technologies Limited. - The new corporate office address is located in Kokapet, Ranga Reddy District, Telangana - 500075. - The change is effective from December 1, 2026.

Business Update Neutral

2026-11-03 18:52

- Krsnaa Diagnostics Limited has submitted the audio recording link of the earnings conference call held on November 3, 2026, for the quarter and half year ended September 30, 2026. - The recording is accessible on the company website.

Routine Neutral

2026-11-03 18:18

- Krsnaa Diagnostics Limited submitted a certificate from statutory auditors M/s. Kirtane & Pandit LLP. - The certificate confirms compliance with Regulation 169(4) of SEBI (ICDR) Regulations, 2018. - The filing is made pursuant to Regulation 169(5) of the SEBI ICDR Regulations.

Business Update Positive

2026-11-03 14:40

Order Win: Krsnaa Diagnostics Limited won Letter of Award from Municipal Corporation of Delhi (MCD) for CT Scan and MRI facilities Order Value: Consideration cannot be determined upfront as revenues depend on actual number of investigations undertaken Completion Timeline: Service Provider Agreement to be executed within 30 days and Commercial Operation Date within 180 days of Site Handover Additional Details: 10-year concession period extendable by up to 5 years on a cash-based PPP model across three public hospitals in Delhi

Financials Neutral

2026-11-02 18:49

Q2 FY27 Consolidated Revenue ₹2,710 Mn vs ₹2,060 Mn (▲32% YoY) EBITDA ₹719 Mn vs ₹602 Mn (▲19% YoY) PAT ₹246 Mn vs ₹239 Mn (▲3% YoY) EBITDA Margin 27% vs 29% (▼200bps)

Business Update Neutral

2026-11-02 18:48

- Q2 FY27 Consolidated Revenue increased 32% YoY to ₹2,710 Mn compared to ₹2,060 Mn in Q2 FY26. - EBITDA stood at ₹719 Mn (up 20% YoY), while PAT rose 3% YoY to ₹246 Mn. - Retail diagnostic revenue grew 35% YoY to ₹235 Mn. - Margin moderation was driven by upfront costs for Rajasthan labs.

Financials Neutral

2026-11-02 15:10

Q2 FY27 Consolidated Revenue ₹270.97Cr vs ₹205.99Cr (▲31.5% YoY) EBITDA ₹71.12Cr vs ₹59.17Cr (▲20.2% YoY) PAT ₹24.59Cr vs ₹23.95Cr (▲2.7% YoY) EBITDA Margin 26.25% vs 28.72% (▼247bps)

Business Update Neutral

2026-10-27 16:56

Concall Schedule Concall Date: November 03, 2026 Concall Time: 12:30 PM IST

Business Update Positive

2026-10-22 07:37

Krsnaa Diagnostics has announced a strategic AI collaboration with global medical imaging AI innovator AZmed. - The partnership will evaluate AZmed’s 'AZtrauma' solution (part of its Rayvolve AI suite) for detecting fractures, joint effusions, and dislocations on X-rays. - Krsnaa processes over 5 million X-rays annually and aims to enhance reporting efficiency, productivity, and scalability. - The collaboration intends to leverage AI within India's healthcare ecosystem while maintaining the central role of radiologists in clinical decisions.

Routine Neutral

2026-10-14 14:12

- Krsnaa Diagnostics Limited issued a clarification regarding the allotment of fully convertible warrants on a preferential basis. - The warrant allotment premium was inadvertently mentioned as ₹551 per warrant in the previous intimation. - The correct warrant allotment premium is ₹561 per warrant. - The error was purely typographical and all other details remain unchanged.

Ownership Positive

2026-10-13 19:26

- Krsnaa Diagnostics Limited has allotted 16,21,000 fully convertible warrants on a preferential basis to promoter and promoter group entities. - The warrants are priced at ₹566 per warrant, aggregating to ₹22.94 crores (25% upfront subscription amount received). - Warrants are convertible into equity shares within 18 months from the date of allotment upon payment of the remaining 75%.

Ownership Positive

2026-10-09 19:27

- Krsnaa Diagnostics Limited has received a corrected in-principle approval letter from BSE Limited. - The approval pertains to the issuance of 16,21,000 convertible warrants on a preferential basis to the Promoter and Promoter Group. - Each warrant is convertible into equity shares of face value ₹5 at an issue price of ₹566 each.

Ownership Positive

2026-10-08 21:43

- Krsnaa Diagnostics Limited received in-principle approval from BSE and NSE for issuing 16,21,000 convertible warrants on a preferential basis to the Promoter and Promoter Group. - The warrants have a face value of ₹5 each at an issue price of ₹566 each. - The BSE approval letter requires rectification due to factual errors and will be resubmitted.

Ownership Positive

2026-10-08 21:11

- Krsnaa Diagnostics Limited has received in-principle approval from BSE and NSE for the issuance of 16,21,000 convertible warrants on a preferential basis. - Warrants are to be issued to the Promoter and Promoter Group at an issue price of ₹566/- each, convertible into equity shares of face value ₹5/- each. - The BSE approval letter contains factual errors and a corrected letter will be intimated separately upon receipt.

Governance Neutral

2026-09-30 20:26

- Krsnaa Diagnostics Limited submitted a revised intimation under Regulation 44(3) of SEBI LODR Regulations for its 16th Annual General Meeting held on September 28, 2026. - The revision rectifies an unintentional error where the promoter/promoter group interest field was erroneously marked as 'Yes' instead of 'No'. - The company clarified that this correction does not affect the voting results, Scrutinizer's Report, or the outcome of any resolution.

Governance Neutral

2026-09-30 13:28

- Appointment of M/s Kirtane & Pandit LLP as the Statutory Auditor of the Company. - Approved by members at the 16th Annual General Meeting held on September 28, 2026. - Appointed for a first term of 5 consecutive years from the conclusion of the 16th AGM until the 21st AGM.

Business Update Positive

2026-09-28 19:03

- Krsnaa Diagnostics Limited approved the sale of identified diagnostic equipment for up to ₹120 crore. - The transaction aims to optimize the asset portfolio, enhance capital efficiency, and transition towards an asset-light model. - The assets are freehold and unencumbered, meaning no impact on lender security packages. - The capital raised will be reinvested into the core diagnostic business and growth opportunities.

Ownership Neutral

2026-09-19 14:27

- Trading Window for dealing in securities will close from September 22, 2026. - It will reopen 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026. - Designated persons are restricted from trading during this period.

Governance Positive

2026-09-18 22:00

- Krsnaa Diagnostics announced the voting results of its Postal Ballot, conducted via remote e-voting from August 19, 2026, to September 17, 2026. - The Special Resolution for the issuance of up to 16,21,000 Warrants convertible into Equity Shares to the Promoter and Promoter Group on a Preferential Basis was passed with requisite majority. - 92.6895% of the total valid votes were cast in favour of the resolution.

Business Update Positive

2026-09-16 16:57

- Krsnaa Diagnostics Ltd. secured a Concession Agreement from the Department of Health & Family Welfare, Government of Punjab (through Punjab Health Systems Corporation). - The agreement is for the development, operation, and maintenance of PET-CT Diagnostic Facilities at 4 Government Hospitals in Punjab. - The project operates under a Public Private Partnership (PPP) model (Design, Build, Finance, Operate, Maintain and Transfer - DBFOT format). - Concession Period: 15 years, providing long-term revenue visibility. - Order Value: Not determinable upfront, revenues are dependent on the actual number of PET-CT scans undertaken and applicable user charges.

Governance Neutral

2026-09-11 14:04

- Krsnaa Diagnostics Limited announced its 16th Annual General Meeting (AGM) to be held on Monday, September 28, 2026, at 11:00 AM IST. - The Annual Report for FY 2025-26 and AGM notice are being circulated to shareholders, with a weblink provided for accessing the documents.

Business Update Negative

2026-09-09 22:58

CRITICAL RED FLAG DETECTED

- Krsnaa Diagnostics received appellate orders from the Commissioner of Income Tax (Appeals) for assessment years 2017-18 to 2023-24. - The aggregate disputed demand reflected in these orders is ₹62.69 Crores. - The company intends to appeal these orders to the Income Tax Appellate Tribunal (ITAT), believing it has strong grounds and expects substantial relief. - The company states these matters do not impact ongoing operations.

Ownership Neutral

2026-08-28 16:14

- Krsnaa Diagnostics issued a Corrigendum to its Postal Ballot Notice dated August 13, 2026, as requested by NSE. This provides additional details for the proposed preferential issue of 16,21,000 share warrants to Promoter and Promoter Group members. The aggregate shareholding of the Promoter and Promoter Group will increase from 27.11% to 29.70% post-issue (fully diluted basis).

Business Update Negative

2026-08-26 22:03

CRITICAL RED FLAG DETECTED

- Krsnaa Diagnostics received an order from the Income Tax Dept. on Aug 14, 2026, for AY 2022-23. - The order rectifies tax computation, resulting in a differential/additional demand of ₹12,09,98,110/-. - The company will file an appeal/rectification against this demand.

Ownership Positive

2026-08-20 14:38

- Krsnaa Diagnostics Ltd. announced a preferential issue of up to 16,21,000 Warrants for ₹91,74,86,000/-. - Each Warrant is priced at ₹566/- and is convertible into one equity share (face value ₹5) within 18 months from allotment. - The Warrants will be allotted to Mr. Rajendra Mutha and Krsnaa Diagnostics (Mumbai) Private Limited.

Business Update Positive

2026-08-19 16:43

- Q1 FY27 revenue grew approximately 22% YoY, with like-to-like projects growing 12% and retail business growing 64% YoY. - EBITDA margin compressed to 25% from 27% YoY due to upfront costs for new project implementations (e.g., Rajasthan manpower onboarding), but is expected to become EBITDA positive by Q2 and reach double digits by year-end. - Rajasthan PPP project's Q1 FY27 revenue was ₹26 Cr, expected to double in Q2, with an annualized expectation of ₹100-150 Cr for FY27. - The company was awarded the Himachal Pradesh CT project (34 CT scans) and operationalized 8 MRI centers in Maharashtra. - Receivables from Himachal Pradesh and Karnataka are being addressed, with funds flowing in/allocated and expected recovery by Q2. - Promoters infused funds via warrants for capital expenditure and potential acquisitions. - Management's focus for coming quarters is on execution, utilization, profitability, and sustainable growth.

Ownership Positive

2026-08-18 17:47

- Krsnaa Diagnostics Limited issued a Postal Ballot notice for approval to issue up to 16,21,000 Warrants convertible into Equity Shares on a preferential basis to its Promoter and Promoter Group. - The issue price is Rs. 566/- per Warrant, aggregating up to Rs. 91.75 crore. - E-voting commences on August 19, 2026, and ends on September 17, 2026.

Business Update Neutral

2026-08-14 17:29

- Krsnaa Diagnostics provides the audio recording of its earnings conference call for the quarter ended June 30, 2026, held on August 14, 2026. - The recording is available on the company's website.

Financials Neutral

2026-08-14 00:11

- Q1 FY27 Consolidated Revenue ₹2,355Mn vs ₹1,930Mn (▲22% YoY) - EBITDA ₹588Mn vs ₹524Mn (▲12% YoY) - PAT ₹166Mn vs ₹205Mn (▼19% YoY) - EBITDA Margin 25% vs 27% (▼221bps)

Financials Positive

2026-08-13 23:53

- Q1 FY27 Consolidated Revenue ₹235.5Cr vs ₹193.0Cr (▲22% YoY) - EBITDA ₹58.8Cr vs ₹52.4Cr (▲12% YoY) - PAT ₹16.6Cr vs ₹20.5Cr (▼19% YoY) - EBITDA Margin 25% vs 27% (▼200bps) - Revenue growth driven by established business and newly commissioned projects. - Rajasthan pathology network became operational, contributing ₹25.7 Cr revenue in Q1. - PAT and EBITDA margin contracted due to upfront fixed costs for new Rajasthan operations ahead of full utilisation. - Retail revenue grew 64% YoY to ₹19.3 Cr, expanding to over 4,250 touchpoints. - Board approved preferential warrant issue to Promoter and Promoter Group, reaffirming confidence.

Financials Negative

2026-08-13 23:46

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹235.53Cr vs ₹192.98Cr (▲22.05% YoY) - EBITDA ₹57.99Cr vs ₹51.40Cr (▲12.80% YoY) - PAT ₹16.55Cr vs ₹20.52Cr (▼19.43% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Board recommended a final dividend of INR 2.00 per equity share for FY 2024-25. - Board approved issuance of 1,621,000 share warrants to promoter group at a price not less than INR 565/-. - Company received income tax demand of ₹626.90 million for multiple assessment years (AY 2017-18 to 2023-24) due to search and seizure proceedings. Company has filed appeals.

Financials Negative

2026-08-13 23:40

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹2,355.32Mn vs ₹1,929.78Mn (▲22.05% YoY) - EBITDA ₹579.85Mn vs ₹514.04Mn (▲12.80% YoY) - PAT ₹165.51Mn vs ₹205.20Mn (▼19.34% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - The Board recommended a final dividend of INR 2.00/- per equity share for FY 2024-25, with a record date of September 18, 2026. - The 16th AGM will be held on Monday, September 28, 2026, at 11:00 Hrs. (IST) in Physical Mode. - Approved the issuance of 1,621,000 share warrants to promoter/promoter group at an issue price higher of the floor price or Rs. 565/-. - Income Tax Authorities issued assessment orders for AY 2017-18 to AY 2023-24 for undisclosed income and disallowance of deductions, resulting in a demand of ₹626.90Mn. The company has filed appeals and deposited ₹102.77Mn under protest, with management believing the impact will not be material.

Financials Negative

2026-08-13 23:34

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹235.53 Cr vs ₹192.98 Cr (▲22.05% YoY) - EBITDA ₹57.99 Cr vs ₹51.40 Cr (▲12.80% YoY) - PAT ₹16.55 Cr vs ₹20.52 Cr (▼19.34% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Board recommended a final dividend of INR 2.00/- per equity share for FY 2024-25. - The 16th Annual General Meeting (AGM) will be held on Monday, September 28, 2026, at 11:00 Hrs (IST) in Physical Mode. - Approved issuance of 1,621,000 share warrants to Promoter and Promoter Group at an issue price higher than INR 565/-. - Income Tax authorities issued demand orders of INR 62.69 Cr for various assessment years due to undisclosed income and disallowances from search proceedings. The company has filed appeals against these orders.

Financials Negative

2026-08-13 23:27

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹2,355.32Mn vs ₹1,929.78Mn (▲22.05% YoY) - EBITDA ₹579.80Mn vs ₹513.96Mn (▲12.81% YoY) - PAT ₹165.51Mn vs ₹205.20Mn (▼19.47% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Notice of the 16th AGM on September 28, 2026, at 11:00 Hrs (IST). Final dividend of INR 2.00/- per share for FY 2024-25 recommended, with September 18, 2026, as record date. - Board approved issuance of 1,621,000 share warrants to promoter group at an issue price higher of floor price or Rs. 565/-. - Company received demand order of INR 626.90 million from Income Tax authorities following search proceedings (AY 2017-18 to AY 2023-24). Appeals filed, INR 102.77 million deposited under protest. Management views impact as immaterial.

Financials Negative

2026-08-13 23:21

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Operating Revenue ₹235.53 Cr vs ₹192.98 Cr (▲22.05% YoY) - EBITDA ₹57.99 Cr vs ₹51.40 Cr (▲12.80% YoY) - PAT ₹16.55 Cr vs ₹20.52 Cr (▼19.44% YoY) - EBITDA Margin 24.62% vs 26.64% (▼202bps) - A final dividend of INR 2.00/- per share for FY 2024-25 was recommended. - Board approved preferential issuance of 1,621,000 share warrants to Promoter and Promoter Group at a floor price of INR 565/-. - The 16th AGM is scheduled for Monday, September 28, 2026, at 11:00 Hrs (IST). - Income Tax Authorities issued a demand order of INR 626.90 Mn for undisclosed income and disallowed deductions following search and seizure proceedings. The company has filed appeals.

Routine Neutral

2026-08-07 19:49

New Filing detected. See link for details.

Business Update Positive

2026-07-23 19:07

- Order Win: Krsnaa Diagnostics Limited entered into a Public Private Partnership (PPP) Agreement with the Director Health Services, Health & Family Welfare Department, Government of Himachal Pradesh. - Project Scope: To set up, operate, manage, maintain, and report CT Scan Diagnostic Facilities at 34 Government Health Institutions, expanding from the previous 12 institutions. - Project Duration: Initial period of seven years, extendable by a further three years. - Order Value: Not estimable as it is a new project.

Governance Neutral

2026-07-06 20:12

- Krsnaa Diagnostics Ltd. announced the passing of all four special resolutions via Postal Ballot on July 04, 2026. These include the re-appointment of Mr. Chetan Desai and appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors, and approval of their remuneration.

Financials Neutral

2026-06-29 17:38

- ICRA Limited reaffirmed the long-term rating of ICRA A (Stable) and short-term rating of ICRA A1 for Krsnaa Diagnostics' ₹304.15 Cr bank facilities. - The outlook on the long-term rating is Stable.

Ownership Neutral

2026-06-24 22:04

- Trading window for Krsnaa Diagnostics Ltd. closed from July 01, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. - Applies to Directors, KMP, Designated Employees, Promoters, and their relatives to prevent insider trading.

KRSNAA

Krsnaa Diagnostics Limited

Price Chart

Filing History

Unlock Full History